Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma.
Vinzolidine, a semisynthetic vinblastine derivative, was tested in an oral formulation in 21 heavily pretreated patients with lymphoma. Partial remissions were seen in four patients with Hodgkin's disease (50%) and in one patient with non-Hodgkin's lymphoma (8%). Significant side effects included neurotoxicity and dose-related myelosuppression. Vinzolidine is an active vinca alkaloid which merits further evaluation in patients with lymphoma, particularly Hodgkin's disease.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D004305:Dose-Response Relationship, Drug; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014748:Vinca Alkaloids / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014748:Vinca Alkaloids; C042392:vinzolidine